Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy ...
Combination therapies targeting pancreatic cancer's extracellular stroma and membrane receptors show promise. Hyaluronidase and anti-PD-L1/PD-1 antibodies enhance tumor growth inhibition. IL-6 blockade with anti-PD-L1 improves survival. VDR ligands and TGF-β inhibitors combined with checkpoint inhibitors increase T cell infiltration. CD40 agonists and CXCR4 inhibitors with anti-PD-1 show potential in enhancing anti-tumor immunity. FAK and BTK inhibitors, alongside PARP inhibitors, are being explored for their roles in improving treatment efficacy.
Reference News
Combination therapies targeting pancreatic cancer's extracellular stroma and membrane receptors show promise. Hyaluronidase and anti-PD-L1/PD-1 antibodies enhance tumor growth inhibition. IL-6 blockade with anti-PD-L1 improves survival. VDR ligands and TGF-β inhibitors combined with checkpoint inhibitors increase T cell infiltration. CD40 agonists and CXCR4 inhibitors with anti-PD-1 show potential in enhancing anti-tumor immunity. FAK and BTK inhibitors, alongside PARP inhibitors, are being explored for their roles in improving treatment efficacy.